ABX-001 / Abalos Therapeutics - LARVOL DELTA

The company recently announced the initiation of a Phase 1 first-in-human study evaluating ABX-001 as a monotherapy in patients with refractory/relapsed advanced solid tumors (GlobeNewswire)

Trial status • Solid Tumor

Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025 (GlobeNewswire) - "In in vivo and in vitro experiments, ABX-001 showed preferential replication in tumor cells, with minimal effects in healthy tissues. ABX-001 recruits, activates and expands CD8+ T-cells, increasing tumor infiltration and causing differentiation of these T-cells into potent effector cells with strong anti-tumoral activity."

Preclinical • Solid Tumor